肿瘤细胞治疗研究
ALL SOURCES
Preclinical development of three novel CARs targeting CD79b for the treatment of non-Hodgkin's lymphoma and characterization of the loss of the target
基于特异性、疗效和靶抗原丢失，CARLY3 代表了一种针对非霍奇金淋巴瘤的潜在新型 CAR 治疗。
CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia
我们开展了一项针对复发或难治性B-ALL儿童及年轻成人患者（n = 15）的1期试验，以测试AUTO3——表达抗CD19和抗CD22 CAR的自体转导T细胞（AMELIA试验，EUDRA CT 2016-004680-39）。
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymph
在这项国际性回顾性分析中，分析了39名儿童和年轻成人，他们在T细胞采集前（n = 12）和/或后（n = 27）接受InO作为CART-19治疗的桥接治疗。
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial.
年龄 1-18 岁、R/R CD22⁺ BCP-ALL 患者按 RP2D 1.8 mg/m² 接受治疗。
CAR-T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia.
CD19 CAR-T细胞在儿童和成人R/R B-ALL患者中均诱导高比例（80-90%）的完全缓解。
CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.
这种癌症可发生于任何年龄的儿童，但在 5 岁以下相当罕见。
共 6 条
MEMBER ACCOUNT
登录成功会直接打开下一页。
